Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...
New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable ...
The year 2015 marked the inception of Sanyou Bio's technological journey, laying the foundation for its core technology platform. The R&D team devoted itself to the development of display vectors, ...
Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) have been assigned an average recommendation of “Buy” ...
Boston: Alloy Therapeutics Inc., a biotechnology ecosystem company has announced its latest strategic collaboration with ...
The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.
Alloy Therapeutics enters multi-year collaboration with Pfizer to develop new antibody discovery platform: Boston, Massachusetts Thursday, February 13, 2025, 13:00 Hrs [IST] Alloy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback